SCHEMBL5030950

SCHEMBL5030950

NC(=O)c1sc2nc(-c3cccs3)nc(-c3cccc(NC(=O)CBr)c3)c2c1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.51
LIMK1 P53667 1/20 0.47
IKBKB O14920 1/20 0.47
PDE4A P27815 3/20 0.45
PDE4B Q07343 3/20 0.45
PDE4C Q08493 3/20 0.45
PDE4D Q08499 3/20 0.45
HPGD P15428 4/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5030959 0.89 LHCGR (0.51) BRAFHPGDMEN1POLBKMT2A
SCHEMBL5024685 0.88 BRAF (0.58) BRAFLIMK1IKBKBPDE4APDE4B
SCHEMBL5026948 0.88 BRAF (0.52) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL5028885 0.86 BRAF (0.48) BRAFLIMK1IKBKBPDE4APDE4B
SCHEMBL5030868 0.86 BRAF (0.46) BRAFLIMK1IKBKBPDE4APDE4B
SCHEMBL5026907 0.86 BRAF (0.48) BRAFLIMK1IKBKBPDE4APDE4B
SCHEMBL5024656 0.84 LIMK1 (0.52) BRAFLIMK1IKBKBPDE4APDE4B
SCHEMBL5026126 0.83 BRAF (0.59) BRAFLIMK1IKBKBPDE4APDE4B
SCHEMBL5024555 0.81 LHCGR (0.55) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL5030954 0.80 LHCGR (0.51) BRAFHPGDMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375109-B2 Glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity N.V. ORGANON (NL) 2008-05-20 US disclosed
EP-1427734-B1 GLYCINE-SUBSTITUTED THIENO[2,3-d]PYRIMIDINES WITH COMBINED LH AND FSH AGONISTIC ACTIVITY AKZO NOBEL NV (NL) 2005-11-09 EP disclosed
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity MERCK SHARP & DOHME B.V. (NL) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180907-A1 Glycine-substituted thieno{2,3-d}pyrimidines with combined lh and fsh agonistic activity FSHR, GNRHR, LHCGR BRAF 4677/4885LIMK1 4850/4885IKBKB 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.